Table of Content

1. Methodology and Scope
1.1. Research Methodology
1.2. Research Objective and Scope of the Report
2. Market Definition and Overview
3. Executive Summary
4. Market Dynamics
4.1. Market Impacting Factors
4.1.1. Drivers:
4.1.1.1. Rising demand for irritable bowel syndrome therapies
4.1.1.2. Increasing technological advancements
4.1.2. Restraints:
4.1.2.1. Scarcity of particular treatment
4.1.3. Opportunity
4.1.4. Impact Analysis
5. Industry Analysis
5.1. Porter’s Five Forces Analysis
5.2. Regulatory Analysis
5.3. Supply Chain Analysis
5.4. Pricing Analysis
6. By Disease Type
6.1. Introduction
6.1.1. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Disease Type Segment
6.1.2. Market Attractiveness Index, By Disease Type Segment
6.2. IBS with Diarrhea (IBS-D)
6.2.1.1. Introduction
6.2.1.2. Market Size Analysis, US$ Million, 2020-2029 and Y-o-Y Growth Analysis (%), 2021-2029
6.3. IBS with Constipation (IBS-C)
6.4. Mixed-Presentation IBS (IBS-M)
7. By Drug Type
7.1. Introduction
7.1.1. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Drug Type Segment
7.1.2. Market Attractiveness Index, By Drug Type Segment
7.2. Rifaximin
7.2.1.1. Introduction
7.2.1.2. Market Size Analysis, US$ Million, 2020-2029 and Y-o-Y Growth Analysis (%), 2021-2029
7.3. Eluxadoline
7.4. Lubiprostone
7.5. Linaclotide
7.6. Others
8. By Distribution Channel
8.1. Introduction
8.1.1. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Distribution Channel Segment
8.1.2. Market Attractiveness Index, By Distribution Channel Segment
8.2. Hospitals Pharmacies
8.2.1.1. Introduction
8.2.1.2. Market Size Analysis, US$ Million, 2020-2029 and Y-o-Y Growth Analysis (%), 2021-2029
8.3. Drug Stores & Retail Pharmacies
8.4. Online Pharmacies
8.5. Others
9. By Region
9.1. Introduction
9.1.1. Market Size Analysis, US$ Million, 2020-2029 and Y-o-Y Growth Analysis (%), 2021-2029, By Region
9.1.2. Market Attractiveness Index, By Region
9.2. North America
9.2.1. Introduction
9.2.2. Key Region-Specific Dynamics
9.2.3. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Disease Type
9.2.4. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Drug Type
9.2.5. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Distribution Channel
9.2.6. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Country
9.2.6.1. U.S.
9.2.6.2. Canada
9.2.6.3. Mexico
9.3. Europe
9.3.1. Introduction
9.3.2. Key Region-Specific Dynamics
9.3.3. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Disease Type
9.3.4. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Drug Type
9.3.5. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Distribution Channel
9.3.6. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Country
9.3.6.1. Germany
9.3.6.2. U.K.
9.3.6.3. France
9.3.6.4. Italy
9.3.6.5. Spain
9.3.6.6. Rest of Europe
9.4. South America
9.4.1. Introduction
9.4.2. Key Region-Specific Dynamics
9.4.3. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Disease Type
9.4.4. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Drug Type
9.4.5. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Distribution Channel
9.4.6. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Country
9.4.6.1. Brazil
9.4.6.2. Argentina
9.4.6.3. Rest of South America
9.5. Asia Pacific
9.5.1. Introduction
9.5.2. Key Region-Specific Dynamics
9.5.3. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Disease Type
9.5.4. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Drug Type
9.5.5. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Distribution Channel
9.5.6. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Country
9.5.6.1. China
9.5.6.2. India
9.5.6.3. Japan
9.5.6.4. Australia
9.5.6.5. Rest of Asia Pacific
9.6. Middle East and Africa
9.6.1. Introduction
9.6.2. Key Region-Specific Dynamics
9.6.3. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Disease Type
9.6.4. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Drug Type
9.6.5. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Distribution Channel
10. Competitive Landscape
10.1. Key Developments and Strategies
10.2. Company Share Analysis
10.3. Disease Types Benchmarking
10.4. List of Key Companies to Watch
11. Company Profiles
11.1. Abbott Laboratories
11.1.1. Company Overview
11.1.2. Disease Type Portfolio and Description
11.1.3. Key Highlights
11.1.4. Financial Overview
11.2. Allergan plc
11.3. Ardelyx Inc.
11.4. Astellas Pharma Inc.
11.5. AstraZeneca plc
11.6. GlaxoSmithKline Plc
11.7. Novartis AG
11.8. Takeda Pharmaceutical Company Limited
11.9. Sebela Pharmaceuticals Inc.
11.10. Ironwood Pharmaceuticals, Inc.
LIST NOT EXHAUSTIVE
12. Global Irritable Bowel Syndrome Treatment Market – DataM
12.1. Appendix
12.2. About Us and Distribution Channel
12.3. Contact Us